Skip to main content

Table 2 Estimated risk of blindness per 1000 population in four scenarios based on high and low prevalence of loiasis and onchocerciasis, under conditions of: 1) no mass treatment with Mectizan®; 2) mass treatment with no risk reduction strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa encephalopathy.

From: A Framework for Decision-Making for Mass Distribution of Mectizan® in Areas Endemic for Loa loa

Loiasis Prevalence High High Low Low
Onchocerciasis Prevalence High Low High Low
No Mectizan® treatment 166.0 94.0 166.0 94.0
Mectizan® treatment     
   No risk reduction strategy 58.1 32.9 58.1 32.9
   REA 58.7 35.5 58.7 35.5
   RAPLOA-40 58.1 32.9 58.1 32.9
   RAPLOA-20 58.1 32.9 58.1 32.9
   REA/RAPLOA-40 58.4 33.9 58.2 33.3